Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Scott, P; Herzog, SA; Auranen, K; Dagan, R; Low, N; Egger, M; Heijne, JC.
Timing of bacterial carriage sampling in vaccine trials: a modelling study.
Epidemics. 2014; 9(12):8-17
Doi: 10.1016/j.epidem.2014.08.003
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Herzog Sereina Annik
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Pathogenic bacteria are often asymptomatically carried in the nasopharynx. Bacterial carriage can be reduced by vaccination and has been used as an alternative endpoint to clinical disease in randomised controlled trials (RCTs). Vaccine efficacy (VE) is usually calculated as 1 minus a measure of effect. Estimates of vaccine efficacy from cross-sectional carriage data collected in RCTs are usually based on prevalence odds ratios (PORs) and prevalence ratios (PRs), but it is unclear when these should be measured. We developed dynamic compartmental transmission models simulating RCTs of a vaccine against a carried pathogen to investigate how VE can best be estimated from cross-sectional carriage data, at which time carriage should optimally be assessed, and to which factors this timing is most sensitive. In the models, vaccine could change carriage acquisition and clearance rates (leaky vaccine); values for these effects were explicitly defined (f(acq), 1/f(dur)). POR and PR were calculated from model outputs. Models differed in infection source: other participants or external sources unaffected by the trial. Simulations using multiple vaccine doses were compared to empirical data. The combined VE against acquisition and duration calculated using POR (VE(acq.dur), (1-POR) × 100) best estimates the true VE (VE(acq.dur), (1-f(acq) × f(dur)) × 100) for leaky vaccines in most scenarios. The mean duration of carriage was the most important factor determining the time until VE(acq.dur) first approximates VE(acq.dur): if the mean duration of carriage is 1-1.5 months, up to 4 months are needed; if the mean duration is 2-3 months, up to 8 months are needed. Minor differences were seen between models with different infection sources. In RCTs with shorter intervals between vaccine doses it takes longer after the last dose until VE(acq.dur) approximates VE(acq.dur). The timing of sample collection should be considered when interpreting vaccine efficacy against bacterial carriage measured in RCTs. Copyright © 2014 The Authors. Published by Elsevier B.V. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Carrier State -
- Cross-Sectional Studies -
- Humans -
- Models, Immunological -
- Nasopharynx - microbiology
- Nasopharynx - pathology
- Pneumococcal Infections - immunology
- Streptococcus pneumoniae - immunology
- Vaccines - immunology
- Find related publications in this database (Keywords)
- Vaccine efficacy
- Bacterial pathogens
- Randomised controlled trials
- Methodological research
- Mathematical modelling